JP6063628B2 - ５−アザシチジンを用いる、非小細胞肺癌の治療方法 - Google Patents

５−アザシチジンを用いる、非小細胞肺癌の治療方法 Download PDF

Info

Publication number
JP6063628B2
JP6063628B2 JP2011549167A JP2011549167A JP6063628B2 JP 6063628 B2 JP6063628 B2 JP 6063628B2 JP 2011549167 A JP2011549167 A JP 2011549167A JP 2011549167 A JP2011549167 A JP 2011549167A JP 6063628 B2 JP6063628 B2 JP 6063628B2
Authority
JP
Japan
Prior art keywords
azacytidine
cells
nsclc
cell
aza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011549167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012517427A5 (https=
JP2012517427A (ja
Inventor
エヌ． ングエン アアロン
エヌ． ングエン アアロン
ジェイ． マクベトフ クイルエ
ジェイ． マクベトフ クイルエ
Original Assignee
セルジーン インターナショナル サルル
セルジーン インターナショナル サルル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルジーン インターナショナル サルル, セルジーン インターナショナル サルル filed Critical セルジーン インターナショナル サルル
Publication of JP2012517427A publication Critical patent/JP2012517427A/ja
Publication of JP2012517427A5 publication Critical patent/JP2012517427A5/ja
Application granted granted Critical
Publication of JP6063628B2 publication Critical patent/JP6063628B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011549167A 2009-02-10 2010-02-09 ５−アザシチジンを用いる、非小細胞肺癌の治療方法 Active JP6063628B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15147909P 2009-02-10 2009-02-10
US61/151,479 2009-02-10
PCT/US2010/000361 WO2010093435A1 (en) 2009-02-10 2010-02-09 Methods for treating non-small cell lung cancer using 5-azacytidine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015032530A Division JP2015131822A (ja) 2009-02-10 2015-02-23 ５−アザシチジンを用いる、非小細胞肺癌の治療方法

Publications (3)

Publication Number Publication Date
JP2012517427A JP2012517427A (ja) 2012-08-02
JP2012517427A5 JP2012517427A5 (https=) 2013-03-21
JP6063628B2 true JP6063628B2 (ja) 2017-01-18

Family

ID=42115561

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011549167A Active JP6063628B2 (ja) 2009-02-10 2010-02-09 ５−アザシチジンを用いる、非小細胞肺癌の治療方法
JP2015032530A Pending JP2015131822A (ja) 2009-02-10 2015-02-23 ５−アザシチジンを用いる、非小細胞肺癌の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015032530A Pending JP2015131822A (ja) 2009-02-10 2015-02-23 ５−アザシチジンを用いる、非小細胞肺癌の治療方法

Country Status (5)

Country Link
US (2) US8492361B2 (https=)
EP (1) EP2396007A1 (https=)
JP (2) JP6063628B2 (https=)
CA (1) CA2789365A1 (https=)
WO (1) WO2010093435A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492361B2 (en) 2009-02-10 2013-07-23 Celgene Corporation Methods for treating non-small cell lung cancer using 5-azacytidine
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
CA2849903A1 (en) 2011-09-26 2013-04-04 Celgene Corporation Combination therapy for chemoresistant cancers
TW201700103A (zh) 2011-11-01 2017-01-01 西建公司 利用胞嘧啶核苷類似物之口服配方治療癌症的方法
EP2817029B1 (en) * 2012-02-24 2019-07-10 Signal Pharmaceuticals, LLC Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy
CA2908742C (en) * 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2014180996A1 (en) * 2013-05-10 2014-11-13 Embl Use of 5-azacytidine to inhibit nonsense-mediated rna decay (nmd)
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015195786A2 (en) * 2014-06-17 2015-12-23 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
MX2017002875A (es) * 2014-09-08 2017-05-30 Celgene Corp Metodos para tratar una enfermedad o trastorno usando formulaciones orales de analogos de citidina en combinacion con un anticuerpo monoclonal anti-pd1 o anti-pdl1.
US9801983B2 (en) 2014-12-18 2017-10-31 Cook Medical Technologies Llc Medical devices for delivering a bioactive to a point of treatment and methods of making medical devices
WO2016201337A1 (en) * 2015-06-12 2016-12-15 Immungene, Inc. Engineered antibody-interferon fusion molecules for the treatment of glucose-regulated protein 94 (grp94) expressing cancers
WO2017096357A1 (en) 2015-12-03 2017-06-08 Epidestiny, Inc. Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療
EP3749298B1 (en) * 2018-02-07 2023-04-05 Lovelace Biomedical Research Institute Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer
US10632211B2 (en) 2018-06-11 2020-04-28 The Regents Of The University Of California Demethylation to treat eye disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
EP2211870A1 (en) 2007-11-01 2010-08-04 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
PL3692983T3 (pl) 2008-05-15 2021-12-27 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
US8492361B2 (en) 2009-02-10 2013-07-23 Celgene Corporation Methods for treating non-small cell lung cancer using 5-azacytidine
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof

Also Published As

Publication number Publication date
US8841277B2 (en) 2014-09-23
US20130274219A1 (en) 2013-10-17
EP2396007A1 (en) 2011-12-21
JP2012517427A (ja) 2012-08-02
CA2789365A1 (en) 2010-08-19
US20110319355A1 (en) 2011-12-29
US8492361B2 (en) 2013-07-23
WO2010093435A1 (en) 2010-08-19
JP2015131822A (ja) 2015-07-23

Similar Documents

Publication Publication Date Title
JP6063628B2 (ja) ５−アザシチジンを用いる、非小細胞肺癌の治療方法
JP6162709B2 (ja) シチジンアナログの経口製剤を使用して癌を治療する方法
KR101633134B1 (ko) 시티딘 유사체의 경구 제형 및 그의 사용 방법
JP6033678B2 (ja) 併用療法を用いた治療方法
WO2013022872A1 (en) Gene methylation biomarkers and methods of use thereof
AU2012316266B2 (en) Combination therapy for chemoresistant cancers
AU2012312308B2 (en) Romidepsin and 5-azacitidine for use in treating lymphoma
US20140357567A1 (en) Methods for treating cancers using oral formulations of cytidine analogs
WO2025188680A1 (en) Use of plk1 inhibitor in combination of gemcitabine or carboplatin in treating ovarian carcinoma
EP2711007A1 (en) 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
WO2015195786A2 (en) Methods for treating cancers using oral formulations of cytidine analogs
NZ624323B2 (en) Methods for treating cancers using oral formulations of cytidine analogs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140731

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161219

R150 Certificate of patent or registration of utility model

Ref document number: 6063628

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250